blank
blank

Ethics and regulatory guidance to address the challenges encountered in research on rare diseases in a multinational dimension: the experience of a European funded programme

1:1
This BMC Medical Ethics article examines ethics and regulatory guidance across EJP RD-funded rare disease research projects.

The article analyses 65 projects funded by the European Joint Programme for Rare Diseases (EJP RD) to identify ethics and regulatory issues encountered by researchers and to describe the guidance provided through the programme’s Ethics Follow-up process. Most projects addressed human participants and personal data, including genetic data, biospecimens, children and non-EU country involvement. The abstract reports that EJP RD guidance supported ethics compliance, while regulatory procedures were often overlooked, highlighting a need to strengthen regulatory awareness in rare disease research.

Acces this publication
BMC Medical Ethics

Year of publication

2026

Source

BMC Medical Ethics; publisher: BMC

Author

Annalisa Landi, Yanis Mimouni, Anne Demoisy, Joana Namorado, Silvia Torretta, Annunziata D’Ercole, Marta Del Alamo, Spencer Gibson, Daria Julkowska, Viviana Giannuzzi

You might also be interested in

ERDERA Accelerator webinar (1)

ERDERA launches Ethics & Regulatory webinar series with introductory webinar on ethics across the research continuum

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
webinar series ERDERA

Introductory webinar: Situating ethics in the research continuum

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
EU Flags

European Commission opens call for evidence on future Joint Undertakings

Feedback is open until 14 July 2026, giving stakeholders an early opportunity to comment during the preparation of a likely legislative proposal for a Council regulation.
ECRD 2026

ECRD 2026 in Prague strengthens the push for a coordinated EU Action Plan on rare diseases

On 3–4 June, EURORDIS–Rare Diseases Europe and Orphanet convened the rare disease community at ECRD 2026 in Prague around a shared call for coordinated European action, including the forthcoming European Blueprint for Rare Diseases.

ERDERA's

search form